A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI) ; day:23 ; month:10 ; year:2020 ; pages:1-10
International journal of clinical oncology ; (23.10.2020), 1-10
- Creator
-
Shinozaki, Katsunori
Yamada, Takeshi
Nasu, Junichiro
Matsumoto, Toshihiko
Yuasa, Yasuhiro
Shiraishi, Takeshi
Nagano, Hiroaki
Moriyama, Ichiro
Fujiwara, Toshiyoshi
Miguchi, Masashi
Yoshida, Ryosuke
Nozaka, Kimiyasu
Tanioka, Hiroaki
Nagasaka, Takeshi
Kurisu, Yasuro
Kobayashi, Michiya
Tsuchihashi, Kenji
Inukai, Michio
Kikuchi, Takashi
Nishina, Tomohiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-020-01811-w
- URN
-
urn:nbn:de:101:1-2020120723494800863008
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shinozaki, Katsunori
- Yamada, Takeshi
- Nasu, Junichiro
- Matsumoto, Toshihiko
- Yuasa, Yasuhiro
- Shiraishi, Takeshi
- Nagano, Hiroaki
- Moriyama, Ichiro
- Fujiwara, Toshiyoshi
- Miguchi, Masashi
- Yoshida, Ryosuke
- Nozaka, Kimiyasu
- Tanioka, Hiroaki
- Nagasaka, Takeshi
- Kurisu, Yasuro
- Kobayashi, Michiya
- Tsuchihashi, Kenji
- Inukai, Michio
- Kikuchi, Takashi
- Nishina, Tomohiro
- SpringerLink (Online service)
Other Objects (12)
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study